Details of the Drug
General Information of Drug (ID: DMAEDQG)
| Drug Name |
EMODIN
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
emodin; 518-82-1; Emodol; Schuttgelb; Frangula emodin; Rheum emodin; Frangulic acid; 3-Methyl-1,6,8-trihydroxyanthraquinone; Archin; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; Persian Berry Lake; 1,3,8-Trihydroxy-6-methyl-9,10-anthraquinone; 6-Methyl-1,3,8-trihydroxyanthraquinone; C.I. Natural Yellow 14; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl-; 1,3,8-Trihydroxy-6-methylanthraquinone; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; 4,5,7-Trihydroxy-2-methylanthraquinone; UNII-KA46RNI6HN; C.I. 75440; NSC 622947
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 270.24 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | ||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Coronavirus Disease 2019 (COVID-19) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 1D6Y | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References



